Mallinckrodt plc Ordinary Shares (MNK): Price and Financial Metrics
Mallinckrodt plc Ordinary Shares (MNK)
Today's Latest Price: $2.50 USD
Updated Jul 1 4:10pm
Add MNK to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 214 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
MNK Stock Summary
- MNK's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.29 -- higher than just 5.39% of US-listed equities with positive expected earnings growth.
- The price/operating cash flow metric for Mallinckrodt plc is higher than merely 3.51% of stocks in our set with a positive cash flow.
- MNK's price/sales ratio is 0.07; that's higher than the P/S ratio of just 3.3% of US stocks.
- If you're looking for stocks that are quantitatively similar to Mallinckrodt plc, a group of peers worth examining would be OSMT, SCOR, ROSE, CPLG, and AR.
- Visit MNK's SEC page to see the company's official filings. To visit the company's web site, go to www.mallinckrodt.com.
MNK Stock Price Chart Technical Analysis Charts
MNK Price/Volume Stats
| Current price | $2.50 | 52-week high | $9.20 |
| Prev. close | $2.68 | 52-week low | $1.00 |
| Day low | $2.48 | Volume | 3,411,699 |
| Day high | $2.77 | Avg. volume | 6,997,710 |
| 50-day MA | $3.02 | Dividend yield | N/A |
| 200-day MA | $3.25 | Market Cap | 211.14M |
Mallinckrodt plc Ordinary Shares (MNK) Company Bio
Mallinckrodt Public Limited Company is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. Areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology and pulmonology, neonatal critical care respiratory therapies, and analgesics and central nervous system drugs. The company was founded in 2013 and is based in Dublin, Ireland.
MNK Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $2.50 | $33.75 | 1119% |
We started the process of determining a valid price forecast for Mallinckrodt plc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Mallinckrodt plc ranked in the 87th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. In terms of the factors that were most noteworthy in this DCF analysis for MNK, they are:
- 4% of the company's capital comes from equity, which is greater than only 1.42% of stocks in our cash flow based forecasting set.
- Mallinckrodt plc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -4.32. This coverage rate is greater than that of only 12.33% of stocks we're observing for the purpose of forecasting via discounted cash flows.
- The weighted average cost of capital for the company is 18. This value is greater than 99.57% stocks in the Healthcare sector that generate free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 1095% |
| 1% | 1107% |
| 2% | 1119% |
| 3% | 1131% |
| 4% | 1142% |
| 5% | 1154% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as MNK, try ARGX, SUPN, ASRT, ASNB, and BEAT.
Loading social stream, please wait...